Life Biosciences

At Life Biosciences, the mission is to reverse age-related diseases. The company's platform, termed epigenetic restoration, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect, and has the potential to restore function across many age-related diseases. Life Biosciences is the sole company holding intellectual property covering the therapeutic use of its epigenetic restoration technology, and the only company to receive FDA approval to advance the technology into human clinical studies. Its initial clinical trial targets optic neuropathies (ER-100), with first patient dosed in a Phase 1 trial, though the underlying science has potential application across multiple age-related diseases including MASH and NAION. Life Biosciences is headquartered in Boston, Massachusetts, and closed an $80 million Series D financing to advance its pipeline.